PPARγ Two randomized, double-blind, placebo-controlled trials (RDBPCT) have shown that pioglitazone [peroxisome proliferator-activated receptor gamma (PPARγ) agonist] significantly ameliorated steatosis and necroinflammation compared to placebo in diabetic NASH [24, 25]. The gene discussed is PPARG; the disease is steatosis.